Atherogenic Index of Plasma is Correlated with Prolonged Length of Stay in COVID-19 Patients with Type 2 Diabetes Mellitus

Abstract

Introduction The Atherogenic Index of Plasma (AIP) is a key biomarker for risk assessment in Type 2 Diabetes Mellitus (T2DM). The COVID-19 pandemic highlighted this population's vulnerability, where metabolic dysregulation is linked to severe outcomes. This literature review explores the correlation between AIP, a marker of dyslipidemia, and prolonged length of stay in COVID-19 patients with T2DM.

Methods This comprehensive review analyzes seven key articles published between 2020 and 2024. The analysis examines AIP's role as a predictor for cardiovascular events, its interplay with inflammatory and coagulation markers, and its association with glycemic control and hospitalization duration in diabetic patients during the COVID-19 pandemic.

Results High AIP is an independent predictor for major adverse cardiovascular events in T2DM. COVID-19 infection exacerbates glycemic dysregulation in this population. Elevated inflammatory markers (e.g., CRP, NLR) and coagulation abnormalities are strongly associated with prolonged hospitalization and increased mortality in diabetic COVID-19 patients. AIP, reflecting dyslipidemia, is intrinsically linked to this inflammation and insulin resistance, thus correlating with adverse clinical outcomes like extended hospital stays.

Discussion The evidence suggests AIP reflects a nexus of metabolic and inflammatory disturbances in diabetic patients. In COVID-19, the virus appears to amplify this underlying dysregulation, creating a vicious cycle of poor glycemic control and heightened inflammation that contributes to disease severity and prolonged hospitalization.

Conclusion AIP is a valuable marker correlated with prolonged hospitalization in COVID-19 patients with T2DM, stemming from its link to inflammation and insulin resistance. Management of this high-risk group requires an integrated approach targeting dyslipidemia, inflammation, and hyperglycemia to improve clinical outcomes.